Six patients with rare blood disease are doing well after gene therapy clinical trial
UCLA researchers are part of an international team that reported the use of a stem cell gene therapy to treat nine people with the rare, inherited blood disease known as X-linked chronic granulomatous disease, or X-CGD. Six of those patients are now in remission and have stopped other treatments. Before now, people with X-CGD – which causes recurrent infections, prolonged hospitalizations for treatment, and a shortened lifespan – had to rely on bone marrow donations for a chance at remission.“With this gene therapy, you can use a patient’s own stem cells instead of donor cells for a transplant,” said Dr. Donald Kohn, a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA and a senior author of the new paper,published today in the journal Nature Medicine. “This means the cells are perfectly matched to the patient and it should be a much safer transplant, without the risks of rejection.”People with chronic granulomatous disease, or CGD, have a genetic mutation in one of five genes that help white blood cells attack and destroy bacteria and fungus using a burst of chemicals. Without this defensive chemical burst, patients with the disease are much more susceptible to infections than most people. The infections can be severe to life-threatening, including infections of the skin or bone and abscesses in organs such as lungs, liver or brain. The most common form of CGD is a subtype call...
Publication date: Available online 8 April 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): David Kremer, Vivien Weyers, Joel Gruchot, Peter Göttle, Hans-Peter Hartung, Hervé Perron, Patrick Küry
British Prime Minister Boris Johnson has been moved out of intensive care, his office says
The number of people in intensive care units (ICU) for coronavirus infection in France fell slightly for the first time since the start of the epidemic, but the number of people dying in nursing homes jumped by more than 50 percent over two days, health ministry data showed on Thursday.
The British government defended its early handling of the coronavirus epidemic after a Reuters investigation found its scientific advisers were too slow to communicate their growing concerns about the outbreak to the public and ministers.
With so many of us wrestling with fears and unknowns surrounding the coronavirus pandemic, every throat tickle, nose drip, or cough is suspect: do I have coronavirus? By now, we all know that COVID-19, the illness caused by coronavirus, can cause severe, life-threatening symptoms, although the majority of people who have it will experience a mild to moderate version. Of course, it is spring, so many people may be experiencing their annual springtime tree pollen allergies. Colds also remain common, just as was true before the coronavirus. And although influenza season is coming to an end, perhaps you’ve wondered if so...
Publication date: Available online 8 April 2020Source: Hepatobiliary &Pancreatic Diseases InternationalAuthor(s): Z. Yang, F.Z. Luo, S. Wang, J. Lerut, L. Zhuang, Q.-Y. Li, X. Xu, S.-S. Zheng
Publication date: Available online 8 April 2020Source: Clinics and Research in Hepatology and GastroenterologyAuthor(s): Audrey Payancé, Pierre François Ceccaldi, Emmanuelle De Raucourt, Dominique Valla, Sophie Hillaire, Danielle Dutheil, Virginia Hernandez-Gea, Christophe Bureau, Aurélie Plessier
Publication date: Available online 8 April 2020Source: Clinics and Research in Hepatology and GastroenterologyAuthor(s): Isabelle Ollivier-Hourmand, Nga Nguyen, Andrea De Gottardi, Dominique Valla, Sophie Hillaire, Danielle Dutheil, Christophe Bureau, Virginia Hernandez-Gea, Emmanuelle De Raucourt, Aurélie Plessier
Publication date: Available online 8 April 2020Source: Clinics and Research in Hepatology and GastroenterologyAuthor(s): Irena Jankowska, Piotr Czubkowski, Dariusz Rokicki, Patryk Lipiński, Dorota Piekutowska-Abramczuk, Elżbieta Ciara, Rafał Płoski, Piotr Kaliciński, Marek Szymczak, Joanna Pawłowska, Piotr Socha
Authors: van Kampen V, Hoffmeyer F, Monsé C, Raulf M, Brüning T, Bünger J, Sucker K Abstract Atopic, allergic, and especially asthmatic subjects might be particularly susceptible to sensory irritation induced by airborne chemicals compared to healthy individuals. Therefore, a good characterization of subjects is essential in inhalation exposure studies on sensory irritants. A total of 105 volunteers, 87% of whom reported to be non-allergic, participated in a medical examination that included skin prick test (SPT), measurements of total IgE, specific IgE (sIgE) to an ubiquitous allergen mix (sx1), a...
More News: Allergy | Allergy & Immunology | Babies | Babies Heart Conditions | Biotechnology | Bone Marrow Transplant | Brain | Cardiology | Chemistry | Children | Clinical Trials | Foundation Trusts | France Health | Gene Therapy | Genetics | Grants | Heart | Heart Transplant | Hospitals | Infectious Diseases | Laboratory Medicine | Liver | Liver Transplant | Lung Transplant | Muscular Dystrophy | National Health Service (NHS) | National Institute for Health Research (NIHR) | National Institutes of Health (NIH) | Neurology | Reflex Sympathetic Dystrophy | Skin | Skin Graft | Stem Cell Therapy | Stem Cells | Study | Transplant Surgery | Transplants | UK Health | Universities & Medical Training | Urology & Nephrology